Lilly Backing Leverage Verve's status as a Lilly subsidiary to pursue strategic partnerships with Lilly and other large pharma, enabling faster development, regulatory access, and potential co-commercialization in cardiovascular gene therapies.

ASCVD Focus Verve's pipeline targets key lipid drivers of atherosclerosis (PCSK9, ANGPTL3, and LPA), creating opportunities for collaboration with diagnostics and specialty pharma seeking durable lipid-lowering solutions or companion diagnostics for patient selection.

Funding Advantage With substantial funding and an early-stage revenue profile, Verve may be receptive to licensing or co-development deals that share development costs and milestones, reducing risk for partners while accelerating pipeline progression.

Tech & Ops An established tech stack including cloud, data analytics, and secure infrastructure signals readiness for partners offering data management, AI-enabled drug discovery, and scalable manufacturing support for gene therapies.

Market Position Verve's unique gene-editing approach in cardiovascular disease positions it for CMOs, contract manufacturers, and diagnostics firms to collaborate on manufacturing, regulatory strategy, and downstream commercialization, leveraging Lilly's cardiovascular platform to maximize reach.